# Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

> **NCT07362017** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 300 (estimated)

## Conditions studied

- Moderate-to-severe Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Ponesimod

## Key facts

- **NCT ID:** NCT07362017
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2028-08
- **Final completion:** 2028-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07362017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07362017, "Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07362017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*